Advancing endometrial cancer treatment: exploring immunotherapy and tyrosine kinase inhibitors through clinical cases
Endometrial cancer (EC) is the most common gynaecological malignancy in developed countries, with advanced- stage disease posing significant therapeutic challenges. Standard treatments, including surgery, radiotherapy and chemotherapy, have limited efficacy in recurrent or metastatic cases, necessit...
Saved in:
| Main Author: | Vanda Salutari |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2025-06-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/advancing-endometrial-cancer-treatment-exploring-immunotherapy-and-tyrosine-kinase-inhibitors-through-clinical-cases/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
SPP1 expression indicates outcome of immunotherapy plus tyrosine kinase inhibition in advanced renal cell carcinoma
by: Xianglai Xu, et al.
Published: (2024-12-01) -
Transarterial chemoembolization combined with tyrosine kinase inhibitors and/or immune checkpoint inhibitors induced hypothyroidism is associated with improved overall survival in hepatocellular carcinoma
by: Shengyuan Xu, et al.
Published: (2025-05-01) -
Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study
by: Joohyun Hong, et al.
Published: (2024-03-01) -
Comparative efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors versus tyrosine kinase inhibitors and immune checkpoint inhibitors alone in advanced hepatocellular carcinoma: a systematic review and meta-analysis
by: Hengyu Tian, et al.
Published: (2025-04-01) -
First-line treatment of hepatocellular carcinoma: a propensity-matched analysis of tyrosine kinase inhibitors combined with TACE, with or without PD-1 inhibitors
by: Yanjun Shen, et al.
Published: (2025-05-01)